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 Identifying altered pathways in an individual is important for 
understanding disease mechanisms and for the future application of custom 
therapeutic decisions. Existing pathway analysis techniques are mainly focused on 
discovering altered pathways between normal and cancer groups and are not 
suitable for identifying the pathway aberrance that may occur in an individual 
sample. A simple way to identify individual’s pathway aberrance is to compare 
normal and tumor data from the same individual. However, the matched normal 
data from the same individual is often unavailable in clinical situation. We 
therefore suggest a new approach for the personalized identification of altered 
pathways, making special use of accumulated normal data in cases when a patient’s 
matched normal data is unavailable. The philosophy behind our method is to 
quantify the aberrance of an individual sample's pathway by comparing it to 
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accumulated normal samples. We propose and examine personalized extensions of 
pathway statistics, Over-Representation Analysis (ORA) and Functional Class 
Scoring (FCS), to generate individualized pathway aberrance score (iPAS).  
Collected microarray data of normal tissue of lung and colon mucosa is 
served as reference to investigate a number of cancer individuals of lung 
adenocarcinoma and colon cancer, respectively. Our method concurrently captures 
known facts of cancer survival pathways and identifies the pathway aberrances that 
represent cancer differentiation status and survival. It also provides more improved 
validation rate of survival related pathways than when a single cancer sample is 
interpreted in the context of cancer-only cohort. In addition, our method is useful in 
classifying unknown samples into cancer or normal groups. Particularly, we 
identified ‘amino acid synthesis and interconversion’ pathway is a good indicator 
of lung adenocarcinoma (AUC 0.982 at independent validation). We also suggest a 
new approach for discovering rare mutations that have functional impact in the 
context of pathway by iteratively combining rare mutations until no more 
mutations with pathway impact can be added. The approach is shown to sensitively 
capture mutations that change pathway level gene expression at breast cancer data. 
Clinical importance of the method is providing pathway interpretation of 
single cancer even though its matched normal data is unavailable. 
 
Keywords : Cancer, Gene expression, Pathway analysis, Network analysis, 
Personalized medicine 
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Chapter 1  
Introduction 
The goals of this chapter are to i) review the existing pathway analysis methods 
and ii) discuss limitations of each class of methods, iii) introducing personalization 
challenges in pathway analysis. 
 
1.1 Existing pathway analysis approaches (Group to group) 
Khatri et al. [1] provide comprehensive review for existing pathway analysis 
approaches. They summarized the importance of pathway analysis to understand 
complex biology and introduce key features of pathway analysis. They also provide 
classification of existing pathway analysis techniques into three generations: Over 
representation analysis (ORA), Functional Class Scoring (FCS) and Pathway 
topology based (PT). 
 
1.1.1 Importance of pathway analysis 
Pathway analysis has become the first choice for gaining insight into the 
underlying biology of differentially expressed genes and proteins, as it reduces 
complexity and has increased explanatory power.  
High-throughput sequencing and gene/protein profiling techniques have 
transformed biological research by enabling comprehensive monitoring of a 
biological system. Analysis of high-throughput data typically yields a list of 
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differentially expressed genes or proteins. This list is extremely useful in 
identifying genes that may have roles in a given phenomenon or phenotype. 
However, for many investigators, this list often fails to provide mechanistic 
insights into the underlying biology of the condition being studied. In this way, the 
advent of high-throughput profiling technologies presents a new challenge, that of 
extracting meaning from a long list of differentially expressed genes and proteins. 
One approach to this challenge has been to simplify analysis by grouping long 
lists of individual genes into smaller sets of related genes or proteins. This 
approach reduces the complexity of analysis. Researchers have developed a large 
number of knowledge bases to help with this task. The knowledge bases describe 
biological processes, components, or structures in which individual genes and 
proteins are known to be involved in, as well as how and where gene products 
interact with each other. One example of this idea is to identify groups of genes 
that function in the same pathways. 
Analyzing high-throughput molecular measurements in the context of pathway 
is useful for two reasons. First, grouping thousands of genes, proteins, and/or other 
biological molecules by the pathways they are involved in reduces the complexity 
to just several hundred pathways for the experiment. Second, identifying active 
pathways that differ between two conditions can have more explanatory power 
than a simple list of different genes or proteins 
 
1.1.2 Component of pathway analysis 
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Pathway analysis can be divided into four important components: Gene level 
statistics, Pathway level statistics (Gene set level statistics), Assessing the 
significance and Correction for multiple hypothesis [1]. Jui-Hung et al., [2] 
mentioned the other important component, data processing (Figure 1.1). Data 
processing is practically very important. Thus, we introduce components of 
pathway analysis according to the Jui-Hung’s definition. 
 
Data preprocessing 
There are two important but frequently overlooked data preprocessing 
steps. Normalization allows expression values obtained from different experiments 
to be directly comparable [3, 4]. The expression values of a small, but different set 
of genes may be missing in different microarray experiments due to technical 
issues. Imputation of missing data is thus important for maximal data coverage 
when the results of multiple experiments are compared. A number of methods are 
available for normalization [4, 5], yet this critical step is frequently omitted [3]. 
The most common normalization algorithms—RMA [4] and MAS 5.0 [6]—are 
designed for expression levels generated with microarrays that follow a lognormal 
distribution. Thus it is important to log transform the raw intensity values from 
microarrays. Failure to do so would bias toward high expression values, reducing 
statistical power because of increase in variance [4]. Log transform is also applied 
to RNA-seq data. Expression level determined by RNA-seq is usually quantified in 
Reads Per Kilobase exon Model per million mapped reads (RPKM; density of 
reads that map to a gene normalized for the length of its mature transcript and for 
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the sequencing depth of the experiment [7]), which after log transform correlates 
well with normalized intensity measured with microarray, also after log transform 
[7]. Missing data can be imputed using methods based on K nearest neighbors, 
singular value decomposition, or least square regression models. Least square 
regression algorithms were reported to produce lower estimation error than other 
methods [8, 9]. In this article we use a popular least square regression algorithm, 
LSimpute_gene [10], to impute missing values in all 132 experimental data sets. 
 
Single gene statistics 
The first step in pathway analysis using mRNA data is to compute a gene-
level statistic of differential expression, e.g. a t statistic, a signal to noise ratio 
(mean to standard deviation ratio), a fold change or a Wilcoxon rank sum statistic. 
Because phenotype change can affect different genes in opposite directions, i.e. 
increase the expression levels of some genes while decrease the levels of others, 
and we want to be able to identify the gene sets that contain both types of genes, it 
is desirable to eliminate the direction of differential expression by taking the 
absolute or square of the statistic [11, 12]. However, data transformations that 
eliminate direction—such as absolute values—lead to asymmetrical distributions, 
and can nullify some analytical estimates of significance based on analytical 
background distributions such as the w
2
 test [13,14]  (see ‘Estimating significance’ 
and ‘The validity of analytical background distributions’ sections). The many-to-
many correspondence between genes and probe sets on a microarray creates 
ambiguity in determining expression levels of genes [15,16]. A common practice is 
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to calculate the mean or median expression levels of the probe sets that correspond 
to the same gene; however, doing so usually increases the number of false 
negatives [17]. An alternative is to perform meta analysis [17], using for example, 
the method proposed by Fisher [18] or by Stouffer [19, 20]. Rather than merging 
the expression values directly, these methods merge probe set level statistics. A 
similar problem exists in RNA-seq, where some sequencing reads are mapped to 
multiple genomic locations. Such multi-mappers originate from paralogs, 
segmentally duplicated regions and low sequence complexity [21]. Ignoring 
multimappers reduces sensitivity and undercounts some genes [7]. Strategies for 
assigning multi-mappers are discussed in [7, 21, 22]. 
 
Pathway level statistics (Gene set-level statistics) 
The purpose of a pathway level ( it can also be called as “gene set-level” ) 
statistic is to decide whether a gene set is distinct in some statistically significant 
way. A gene set statistic can be defined in terms of properties of the genes in the 
set, e.g. the mean, median, variance, etc. of a gene-level statistic. When a property 
(and its corresponding statistic) is chosen, the null hypothesis must, of course, also 
be specified. There are two null hypotheses as defined by Tian et al. [23]. In one 
case (Q1) the background distribution is obtained by shuffling genes; in the other 
(Q2), the background distribution is obtained by shuffling phenotypes, i.e. samples 
(see ‘Estimating significance’ section). The rationale for using Q1 is that a 
significant gene set should be distinguishable from an equal size set composed of 
randomly chosen genes. On the other hand,Q2 focuses on a gene set and tests 
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whether its association with the phenotype change is distinguishable from 
randomly shuffled phenotype changes. Q2 is generally favored because it preserves 
the relationship of the genes in the set [23, 24, 25] and directly addresses the 
question of finding gene sets whose expression changes correlates with phenotype 
changes. Gene set-level statistics generally ignore clinical covariates—factors such 
as age, sex and weight—which can also cause differential expression, confounding 
the impact of phenotype changes [26]. The effect of covariates can be estimated 
using, for example, a linear regression model [26]. If a t statistic is used in the gene 
level, it can be generalized using a linear regression model for covariate correction, 
after accounting for the increased number of variables to avoid over fitting [26]. 
Most gene set-level statistics also ignore relationships among genes within the set. 
For example, if the gene set is a pathway, its topological information is ignored. 
Including topological information is important for accounting for the effect of 
genetic buffering [26], which deduces that if a gene fails to propagate its influence 
to a pathway neighbor, its biological role is buffered. Conversely, a gene that 
regulates many of its downstream genes may play a pivotal role in the expression 
changes of the pathway associated with phenotype changes. Methods for including 




One can use significance in the standard way: the probability that the null 
hypothesis, evaluated on the background (or null) distribution, is correct. The 
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background distribution can sometimes be written analytically, as in the case of a 
Gaussian distribution, and it can always be simulated by shuffling experimental 
data. As noted in the above section, simulated background is dictated by the choice 
of the null hypothesis (Q1 or Q2), which often leads to different conclusions [23]. 
Most frequently the gene set-level statistic, e.g. the mean of the t-statistic values of 
genes in the set, is assumed to follow a normal distribution when expression 
change has no association with phenotype change [23]. In such case the 
significance (P-value) ofa gene set can be computed analytically [14]. Such an 
assumption is in question when the expression levels of genes in a set are 
dependent on one another, which is common for genes in a pathway [34]. In ‘The 
validity of analytical background distributions’ section we will discuss analytical 
backgrounds and empirical corrections [14] to make them more useful. To be 
concrete in illustrating how significance is estimated using a simulated background 
distribution, suppose we are interested in estimating the probability that the 
enrichment score obtained for a particular gene set is a chance occurrence of 
phenotype changes. The procedure would be to shuffle the phenotype labels, 
calculate the differential expression of each gene, rank all genes and compute an 
enrichment score for the same gene set. The entire process is repeated multiple 
times to obtain a distribution of enrichment scores, and the P-value of the actual 
enrichment score is simply the fraction of shuffles that produce enrichment scores 
at least as great as observed. Although simulating the background distribution 
obviates the need of an analytical background, it can be computational 
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demanding—at least N shuffles need to be performed to achieve a P-value 
resolution of 1/N [30]. 
 
Correction for multiple testing  
Correction for multiple testing P-value is the appropriate measure of 
statistical significance when only one gene set is tested. When a large number of 
gene sets are tested, there can be many false positives among the gene sets that 
receive seemingly highly significant P-values; this is called the multiple hypothesis 
testing problems. The simplest procedure is to choose a P-value which, when 
multiplied by the number of hypotheses, i.e. the total number of tested gene sets, 
gives a sufficiently low corrected P-value, e.g. <0.05. This Bonferroni correction 
[31] is, however, very conservative and sometimes results in an unacceptably large 
number of false negatives. An alternative is to control the expected fraction of false 
positives among the predictions, or the false discover rate (FDR), using the method 
by Benjamini and Hochberg [32]. The original Benjamini–Hochberg procedure 
assumes a uniform distribution for the P-values [32]. In some cases when there are 
relatively many ‘non-null’ tests, i.e. when low P-values are prevalent, an FDR 
variant, positive FDR (pFDR) can be applied [32, 33]. The corrected P-value is 
called Q-value, defined as the ‘minimum FDR at which a test is called significant’ 
[32, 34]. The relationship between Q-value and FDR is analogous to that between 
P-value and type I error [32]. The final significant gene sets are the ones whose Q-















Figure 1.1 Key components of pathway analysis 
 
Jui-Hung Hung et al. 
Gene set enrichment analysis: performance evaluation and usage guidelines  




1.1.3 Classification of existing pathway analysis approaches  
Existing pathway analysis techniques can further be classified into three 
generations: Over representation analysis (ORA), Functional Class Scoring (FCS) 
and Pathway topology based (PT) [1] (Figure 1.2). List of existing tools collected 
by Khatri et al. for each generation can be found at table 1.1-1.3. 
 
First Generation: Over-Representation Analysis (ORA) Approaches  
The immediate need for functional analysis of microarray gene expression data 
and the emergence of gene ontology (GO) during that period gave rise to over-
representation analysis (ORA), which statistically evaluates the fraction of genes in 
a particular pathway found among the set of genes showing changes in expression. 
It is also referred to as “2×2 table method” in the literature [35]. ORA uses one or 
more variations of the following strategy [36]–[43] (Figure 1.2): first, an input list 
is created using a certain threshold or criteria. For example, a researcher may 
choose genes that are differentially over- or under-expressed in a given condition at 
a false discovery rate (FDR) of 5%. Then, for each pathway, input genes that are 
part of the pathway are counted. This process is repeated for an appropriate 
background list of genes (e.g., all genes measured on a microarray). Next, every 
pathway is tested for over- or under-representation in the list of input genes. The 
most commonly used tests are based on the hypergeometric, chi-square, or 
binomial distribution. We refer the readers to recent comparisons of ORA tools for 
more details [44], [45]. Many of the ORA tools differ very slightly from each other 
as they use the same statistical tests as well as overlapping pathway databases 
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Limitations: Over-Representation Analysis (ORA) Approaches 
Despite the availability of a large number of tools and their widespread usage, 
ORA has a number of limitations. First, the different statistics used by ORA (e.g., 
hypergeometric distribution, binomial distribution, chi-square distribution, etc.) are 
independent of the measured changes. This means that these tests consider the 
number of genes alone and ignore any values associated with them such as probe 
intensities. By discarding this data, ORA treats each gene equally. However, the 
information about the extent of regulation (e.g., fold-changes, significance of a 
change, etc.) can be useful in assigning different weights to input genes, as well as 
to the pathways they are involved in, which in turn can provide more information 
than current ORA approaches.  Second, ORA typically uses only the most 
significant genes and discards the others. For instance, the input list of genes from 
a microarray experiment is usually obtained using an arbitrary threshold (e.g., 
genes with fold-change  and/or p-values). With this method, marginally less 
significant genes (e.g., fold-change = 1.999 or p-value = 0.051) are missed, 
resulting in information loss. Breitling et al. addressed this problem by proposing 
an ORA method for avoiding thresholds. It uses an iterative approach that adds one 
gene at a time to find a set of genes for which a pathway is most significant [46].  
Third, by treating each gene equally, ORA assumes that each gene is independent 
of the other genes. However, biology is a complex web of interactions between 
gene products that constitute different pathways. One goal of gene expression 
analysis might be to gain insights into how interactions between gene products are 
manifested as changes in gene expression. A strategy that assumes the genes are 
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independent is significantly limited in its ability to provide insights in this regard. 
Furthermore, assuming independence between genes amounts to “competitive null 
hypothesis” testing (see below), which ignores the correlation structure between 
genes. Consequently, the estimated significance of a pathway may be biased or 
incorrect.  Fourth, ORA assumes that each pathway is independent of other 
pathways, which is erroneous. For instance, GO defines a biological process as a 
series of events accomplished by one or more ordered assemblies of molecular 
functions (http://www.geneontology.org/GO.doc.shtml). Another example of 
dependence between pathways is the cell cycle pathway in KEGG 
(http://www.genome.jp/kegg/pathway/hsa/hsa04110.html), where the presence of a 
growth factor activates the MAPK signaling pathway. This, in turn, activates the 
cell cycle pathway. No ORA methods account for this dependence between 
molecular functions in GO and signaling pathways in KEGG. 
 
Second Generation: Functional Class Scoring (FCS) Approaches 
The hypothesis of functional class scoring (FCS) is that although large changes 
in individual genes can have significant effects on pathways, weaker but 
coordinated changes in sets of functionally related genes (i.e., pathways) can also 
have significant effects. With few exceptions [47]–[49], all FCS methods use a 
variation of a general framework that consists of the following three steps [11] 
(Figure 1.2): first, a gene-level statistic is computed using the molecular 
measurements from an experiment. This involves computing differential 
expression of individual genes or proteins. Statistics currently used at gene-level 
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include correlation of molecular measurements with phenotype [50], ANOVA [51], 
Q-statistic [47], signal-to-noise ratio [52], t-test [51], [23], and Z-score [53]. 
Although the choice of a gene-level statistic has a negligible effect on the 
identification of significantly enriched gene sets [11], when there are few 
biological replicates, a regularized statistic may be better. Furthermore, 
untransformed gene-level statistics can fail to identify pathways with up- and 
down-regulated genes. In this case, transformation of gene-level statistics (e.g., 
absolute values, squared values, ranks, etc.) is preferable [11], [26].  Second, the 
gene-level statistics for all genes in a pathway are aggregated into a single 
pathway-level statistic. This statistic can be multivariate [49], [54]–[57] and 
account for interdependencies among genes, or it can be univariate [23], [26] and 
disregard interdependencies among genes. The pathway-level statistics used by 
current approaches include the Kolmogorov-Smirnov statistic [52], [58], sum, 
mean, or median of gene-level statistic [26], the Wilcoxon rank sum [59], and the 
maxmean statistic [60]. Irrespective of its type, the power of a pathway-level 
statistic can depend on the proportion of differentially expressed genes in a 
pathway, the size of the pathway, and the amount of correlation between genes in 
the pathway. Interestingly, although multivariate statistics are expected to have 
higher statistical power, univariate statistics show more power at stringent cutoffs 
when applied to real biological data, and equal power as multivariate statistics at 
less stringent cutoffs [61].  The final step in FCS is assessing the statistical 
significance of the pathway-level statistic. When computing statistical significance, 
the null hypothesis tested by current pathway analysis approaches can be broadly 
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divided into two categories: i) competitive null hypothesis and ii) self-contained 
null hypothesis [11], [23], [35], [60]. A self-contained null hypothesis permutes 
class labels (i.e., phenotypes) for each sample and compares the set of genes in a 
given pathway with itself, while ignoring the genes that are not in the pathway. On 
the other hand, a competitive null hypothesis permutes gene labels for each 
pathway, and compares the set of genes in the pathway with a set of genes that are 
not in the pathway. FCS methods address three limitations of ORA. First, they do 
not require an arbitrary threshold for dividing expression data into significant and 
non-significant pools. Rather, FCS methods use all available molecular 
measurements for pathway analysis. Second, while ORA completely ignores 
molecular measurements when identifying significant pathways, FCS methods use 
this information in order to detect coordinated changes in the expression of genes 
in the same pathway. Finally, by considering the coordinated changes in gene 
expression, FCS methods account for dependence between genes in a pathway, 
which ORA does not.   
 
Limitations: Functional Class Scoring (FCS) Approaches 
Although FCS is an improvement over ORA [23], [50], it also has several 
limitations. First, similar to ORA, FCS analyzes each pathway independently. This 
is a limitation because a gene can function in more than one pathway, meaning that 
pathways can cross and overlap. Consequently, in an experiment, while one 
pathway may be affected in an experiment, one may observe other pathways being 
significantly affected due to the set of overlapping genes. Such a phenomenon is 
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very common when using the GO terms to define pathways due to the hierarchical 
nature of the GO.  Second, many FCS methods use changes in gene expression to 
rank genes in a given pathway, and discard the changes from further analysis. For 
instance, assume that two genes in a pathway, A and B, are changing by 2-fold and 
20-fold, respectively. As long as they both have the same respective ranks in 
comparison with other genes in the pathway, most FCS methods will treat them 
equally, although the gene with the higher fold-change should probably get more 
weight. Importantly, however, considering only the ranks of genes is also 
advantageous, as it is more robust to outliers. A notable exception to this scenario 
is approaches that use gene-level statistics (e.g., t-statistic) to compute pathway-
level scores. For example, an FCS method that computes a pathway-level statistic 
as a sum or mean of the gene-level statistic accounts for a relative difference in 
measurements.   
 
Third Generation: Pathway Topology (PT)-Based Approaches  
A large number of publicly available pathway knowledge bases provide 
information beyond simple lists of genes for each pathway. Unlike GO and the 
Molecular Signatures Database (MSigDB), these knowledge bases also provide 
information about gene products that interact with each other in a given pathway, 
how they interact (e.g., activation, inhibition, etc.), and where they interact (e.g., 
cytoplasm, nucleus, etc.). These knowledge bases include KEGG [61], MetaCyc 
[62], Reactome [63], RegulonDB [64], STKE (http://stke.sciencemag.org), 
BioCarta (http://www.biocarta.com), and PantherDB [65].  ORA and FCS 
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methods consider only the number of genes in a pathway or gene coexpression to 
identify significant pathways, and ignore the additional information available from 
these knowledge bases. Hence, even if the pathways are completely redrawn with 
new links between the genes, as long as they contain the same set of genes, ORA 
and FCS will produce the same results. Pathway topology (PT)-based methods 
have been developed to utilize the additional information. PT-based methods are 
essentially the same as FCS methods in that they perform the same three steps as 
FCS methods. The key difference between the two is the use of pathway topology 
to compute gene-level statistics.  Rahnenfuhrer et al. proposed ScorePAGE, 
which computes similarity between each pair of genes in a pathway (e.g., 
correlation, covariance, etc.) [29]. The similarity measurement between each pair 
of genes is analogous to gene-level statistics in FCS methods, which is averaged to 
compute a pathway-level score. However, instead of giving equal weight to all 
pairwise similarities, ScorePAGE divides the pairwise similarities by the number 
of reactions needed to connect two genes in a given pathway (Figure 1.2). 
Although the approach is designed to analyze metabolic pathways, it is 
theoretically also applicable to signaling pathways.  A recent impact factor (IF) 
analytic approach was proposed to analyze signaling pathways. IF considers the 
structure and dynamics of an entire pathway by incorporating a number of 
important biological factors, including changes in gene expression, types of 
interactions, and the positions of genes in a pathway [66], [67] (Figure 1.2). Briefly, 
IF analysis models a signaling pathway as a graph, where nodes represent genes 
and edges represent interactions between them. Further, it defines a gene-level 
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statistic, called perturbation factor (PF) of a gene, as a sum of its measured change 
in expression and a linear function of the perturbation factors of all genes in a 
pathway (see Equation 1 in Appendix). Because the PF of each gene is defined by a 
linear equation, the entire pathway is defined as a linear system. Representing a 
pathway as a linear system also addresses loops in the pathways [67]. The IF of a 
pathway (pathway-level statistic) is defined as a sum of PF of all genes in a 
pathway (see Equation 2 in Appendix). IF analysis was recently improved to 
address the dominating effect of change in expression on PF and high false positive 
rate for a small list of input genes [28].  FCS methods that use correlations among 
genes [50], [68] implicitly assume that the underlying network, as defined by the 
correlation structure, does not change as the experimental conditions change. 
However, this assumption may be inaccurate. For example, the correlation 
structure between ARG2 and other genes in the urea-cycle pathway changes with a 
change in expression of ARG2 [69], suggesting changes in the topology of the 
pathway.  Shojaie et al. proposed a method, called NetGSA, that accounts for the 
the change in correlation as well as the change in network structure as experimental 
conditions change [70]. Their approach, like IF analysis, models gene expression as 
a linear function of other genes in the network. However, it differs from IF in two 
aspects. First, it accounts for a gene's baseline expression by representing it as a 
latent variable in the model. Second, it requires that the pathways be represented as 
directed acyclic graphs (DAGs). If a pathway contains cycles, NetGSA requires 
additional latent variables affecting the nodes in the cycle. In contrast, IF analysis 
does not impose any constraint on the structure of a pathway [67].   
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Limitations: Third Generation: Pathway Topology (PT)-Based Approaches  
Although PT-based methods are difficult to generalize, they have several 
common limitations. One obvious problem is that true pathway topology is 
dependent on the type of cell due to cell-specific gene expression profiles and 
condition being studied. However, this information is rarely available and is 
fragmented in knowledge bases, even if it is fully understood [71]. As annotations 
improve, these approaches are expected to become more useful. Other limitations 
of PT-based methods include the inability to model dynamic states of a system and 
the inability to consider interactions between pathways due to weak inter-pathway 
links to account for interdependence between pathways.  
 
1.1.4 Challenges in pathway analysis 
Khatri et al. introduces two major challenges in pathway analysis: annotation 
challenge and methodological challenge [1]. As pathway is a repository of 
knowledge that is acquired by fundamental evidence from experiments, the 
boundary is limited to the current understanding of Biology.  
The annotation challenges can further be categorized to several challenges such 
as low resolution knowledge bases, incomplete and inaccurate annotations, missing 
condition- and cell-specific information and Inability to model and analyze 
dynamic response. Choosing the right pathway databases, adding manual curation 
for the specific biological problem that pathway analysis be applied will provide 
more accurate results.  
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The methodological challenge can further be classified to three challenges: 
benchmark data sets for comparing different methods, inability to model and 
analyze dynamic response and inability to model effects of an external stimuli. 
Especially, comparing different methods is important for new method development. 
However, the problem of comparing different methods for pathway analysis is 
made difficult by the lack of a gold standard. One can mine the literature to obtain 
evidence on whether a gene set is associated with the phenotype change, but this 
can only be done on a small scale. An alternative is suggested by Jui-Hung et al. to 
quantify the number of overlapping predictions [2].  
However, it is arguable that pathways that have commonly discovered by 
several methods can always be a gold standard. A sensitive method might have 
found the true biological knowledge while others have failed. Thus, we suggest to 
not to consider overlapping pathways from multiple methods as a gold standard. 
Rather than that, we suggest to collect as many as data set that can be used for 
independent validation set for your study. In this paper, we follow this philosophy 
to demonstrate the performance of our method. 
Another important challenge, although it is not mentioned by either of review 
papers [1,2], is personalized pathway analysis. Most pathway analysis methods 
reviewed so far is for discovering aberrant pathway between two phenotype groups. 
Methods can hardly provide the molecular aberrance of a single sample in terms of 






















Figure 1.2 Overview of existing pathway analysis methods using gene expression 
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Figure 1.3 Overview of challenges in pathway analysis: low resolution, missing, and incomplete 
information. Green arrows represent abundantly available information, and red arrows represent 
missing and/or incomplete information. The ultimate goal of pathway analysis is to analyze a 
biological system as a large, single network. However, the links between smaller individual 
pathways are not yet well known. Furthermore, the effects of a SNP on a given pathway are also 
missing from current knowledge bases. While some pathways are known to be related to a few 
diseases, it is not clear whether the changes in pathways are the cause for those diseases or the 
downstream effects of the diseases. 
 
Khatri P, Sirota M, Butte AJ (2012) Ten Years of Pathway Analysis: Current Approaches and 






1.2 Personalized pathway analysis 
Cancer arises from normal cells and can evolve to become malignant, 
metastatic, and/or resistant to therapy. The analysis of altered pathways in an 
individual cancer patient may help to understand the disease status and suggest 
customized anti-cancer therapies.  
It is straightforward to compare the molecular profile of an individual’s tumor 
and normal cells to discover molecular aberrances specific to his/her cancer. 
However, it may not be feasible in the current clinical practice environment to 
perform a metastatic tumor biopsy at the time of treatment resistance in patients 
with advanced cancer [1]. A case study of custom tailored med-icine based on an 
individual’s genome and transcriptome highlights this limitation [2]. A patient’s 
tumor had metastasized to the lung after surgery at the primary site. A biopsy from 
his lung tumor was analyzed by mutation and transcription profiling; however, the 
patient’s normal lung tissue was not biopsied. Since there was no matched normal 
tissue, mRNA expression in the patient’s own blood and information collected 
from various normal tissues were used to identify differentially expressed genes 
(DEGs). The results of pathway analysis based on DEGs, integrated copy number 
variation (CNV), and mutation information led the doctor to change the patient’s 
drug treatment and the disease was stabilized for 3 months.  
Although the personalized interpretation of pathways can be demanding, most 
current pathway analyses have been developed to investigate deregulated pathways 
between two phenotype groups. Khatri et al. [3] classified these methods into three 
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types: Over-Representation Analysis (ORA), Functional Class Scoring (FCS), and 
a Pathway Topology based approach (PT).  
ORA approaches typically apply an arbitrary threshold value (e.g., fold-change 
>2 or P-value <0.05) on gene expression to assess if the number of genes beyond 
threshold are significantly over or under represented in the given pathway. There 
are two drawbacks to ORA. First, it uses only the most significant genes and 
discards others, thus resulting in information loss for marginally significant genes 
[4]. Second, it considers only the number of genes and does not consider the 
magnitude of expression changes, leading to information loss regarding the 
importance of genes (e.g. a gene with a fold change of 2.01 and a gene with a fold 
change of 4 are considered equally). Unlike ORA, FCS methods do not discard 
genes with an arbitrary threshold but use all available genes, which is an 
improvement over ORA [5]. PT methods are essentially based on FCS methods 
with the addition that they consider network topology information. They 
compensate for the common limitation of ORA and FCS in reporting false positive 
gene sets due to sets of overlapping genes. In our paper, we focus on ORA and 
FCS methods, extending and implementing each for personalized pathway analysis.  
There are two exceptional studies examining individualized pathway analysis 
[6],[7]. PARADIGM is a tool that infers a pathway status by using known 
functional structures. The method models the functional structure of pathway as a 
set of interconnected variables, where the variables are omic objects such as DNA, 
mRNA, and Protein where the interaction between variables describes the 
functional status of a pathway. PARADIGM may perform better with multiple 
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omics as it utilizes known functional relationships between a gene or inter-gene 
DNA and protein. Hence, it might not perform well with single layer omic data, 
such as from mRNA microarrays.  
Drier et al. (2013) [7] proposed a personal pathway deregulation score (PDS) 
which represents the distance of a single cancer sample from the median of normal 
samples on the principal curve. To calculate PDS, they reduced the dimensions by 
principal component analysis (PCA) and found the best principal curve, utilizing 
entire cohort samples containing both normal and different stages of cancers. 
Drier’s method performs better than PARADIGM does in the mRNA only data sets 
of brain and colon cancers. However, calculating PDS requires manual data pre-
processing steps, including selecting the number of principal components to be 
used and filtering out noisy gene data to obtain optimized principal curves. PDS 
requires information from whole cohort data to interpret an individual’s pathway, 
which can be a limitation when applied to cohorts with small sample sizes, 
especially, when applied to cohorts that lack normal tissues controls.  
Our proposed method is based on the comparison of one cancer sample to 
many accumulated normal samples (we use “nRef” to refer to the accumulated 
normal samples) that is different from the previous studies in following sense. The 
proposed method is suitable to adopt single layer omics data and expendable to 
interpret a patient in the context of many published or user defined pathway gene 
sets. PARADIGM has less freedom in terms of data and gene sets as it prefers 
multi-layered omics data and requires pre-defined functional structure among 
omics objects. Unlike PDS, which ex-tracts the principal curve from entire cohort 
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data, our method does not assume an individual sample belongs to a cohort. This 
helps to avoid potential risk of dataset dependent analytic bias and also reduces 
efforts for data context dependent optimization process.  
Our method provides a series of analysis steps, which consists of four parts: 
data processing, gene level statistics, individualized pathway aberrance scoring 
(iPAS), and a significance test. To dis-cover the most feasible method for iPAS, we 
extend existing path-way analysis techniques, namely ORA and FCS, to properly 
reflect the nature of testing one cancer to many normal samples.  
To demonstrate that iPAS do indeed capture biologically and clinically 
relevant information in a sensible, valid, and useful manner, we apply it to samples 
of lung and colon adenocarcinoma. We show that our representation generates 
clinically relevant stratifications and outcome predictors, which would not have 
been achieved when the same data is analyzed by the conventional method that 
does not utilize accumulated normal data. We also applied our method to 
investigate functional impact mutations in the context of pathway. 
. 
Our empirical study suggests two different strategies, depending on the 
biological question that iPAS is focused on. In the case of cancer diagnosis, a 
method that utilizes the inter-gene correlation structure of the accumulated normal 
samples performs best. In the case of cancer prognosis, a simple averaging of all 





1.3 Purpose and novelty of this study  
The main purpose of this thesis is to quantify an individual cancer sample’s 
pathway level aberrance. We followed biological insight that every cancer evolves 
from normal cell, inspiring comparison of a single cancer sample to many normal 
samples to quantify the molecular aberrance of single cancer case.  
Our approach is unique in that our interpretation is not data set or cohort 
dependent, but reference dependent. In typical cases, cancer data is provided in the 
cohort study. Multiple cancer samples in the same cohort are usually normalized 
together and further be analyzed for differentially expressed gene analysis. In this 
procedure, a single cancer sample’s expression level is going to be affected by 
other cancer samples in the same data set, thus it is data set dependent 
interpretation. In our analysis, we collect and provide multiple normal samples’ 
data. A single cancer case is compared to many normals to quantify its pathway 
level aberrance. A cancer sample’s expression level is going to be affected by 
normal samples’ data, but it is not affected to other cancers from the same cohort 
where the sample of interest originated from. Thus, interpretation of our method 
can be considered as data set independent.  
To prove that our approach is meaningful and have advantage against 
conventional approach that just use entire cohort for a single cancer case’s 
interpretation, we provide a series of experiments. We have demonstrated that our 
method truly captures previous published biological knowledge, provide improved 
validation rate in the survival analysis than typical approach that utilize entire 
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cohort data set. Additionally, our method is useful to capture the clinical important 
features in an unsupervised clustering of samples. The method is also able to 
capture commonly dysregulated pathways across all cancer samples which would 
not have been captured in the approach using cancer cohort data set. The 
commonly dysregulated pathways discovered by our method is able to classify 
cancer and normal, possibly to be useful for diagnosing cancer. Quantifying an 
individual sample’s pathway level aberrance is also useful to investigate mutational 
impact on the pathways.  
An important clinical aspect of our methods is that it enables the interpretation 
of a cancer case in a single patient, even if matched normal tissue data from the 
same individual is unavailable. Accumulated information of normal tissues from a 
data repository will take the place of data unavailable for a specific individual. As 
the data repository is growing rapidly, it is expected that more normal tissue data 
will be available for many diseases in the near future.  
We hope that our proposed approach can help in the personalized interpretation 
of tumor data and can be a useful tool in the upcoming era of data-based 
personalized medicine. 
  
1.4 Outline of thesis 
This thesis is organized as follows. Chapter 1 is an introduction of this study 
including the review of pathway analysis. Chapter 2 is introducing the approach of 
our study with materials used. Data sets used for this study is provided. Chapter 3 
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is a study of the effects of personalized pathway analysis. In this chapter, firstly, 
validation study of previously published survival related pathways are performed. 
This is to prove our approach is sensitively discovers known biological truth. 
Secondly, we compare our method to conventional approach in terms of validation 
rate of survival related pathways. Thirdly, we tested if unsupervised clustering of 
individualized pathway aberrance score can truly represent clinically important 
cancer characteristics. At fourth, we investigated that our approach is useful to 
diagnose cancer, namely pathway based identification of cancer. At fifth, we 
applied our personalized pathway analysis to discover mutations that have impact 







Methods and materials 
 
2.1 Gene expression data 
 I built nRef by the manual curation of data obtained from NCBI GEO 
[77],[78]. Microarray data of adjacent normal tissues obtained from patients 
undergoing surgery were selected to serve as the nRef. Data from biopsied samples, 
primary cultures of normal tissues and post-mortem donors were not included in 
the nRef. I collected a total of 120 nRef for lung, 60 from GSE19804 [79],[80], 27 
from GSE7670 [81] and 33 from GSE10072 [82]. Samples came from individuals 
with variable smoking histories and different ethnic backgrounds. I collected 101 
nRef’ for colon, concentrating on normal mucosa tissue samples from six data sets 
available at GEO. 
To evaluate the effectiveness of our method in survival analysis, we used 
Beer’s data of 442 lung adenocarcinomas (LUAD) [83] to discover survival related 
pathways and validated the associations of 61 LUAD samples of GSE8894 [84]. 
The pathways identified in of LUAD were tested on 120 cancers and 120 normal 
samples of GSE19804, GSE7670, and GSE10071. Further validation was 
conducted with 48 cancers and 35 normal samples collected from GSE19188 [85] 
and GSE31547. For patient stratification by colon cancer differentiation status, we 
used 566 microarrays of GSE39582 [86], which provided in a separate manner, 443 
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for discovery, 123 for validation. GSE17536 [87] was also used for validation. The 
gene expression data set used is summarized in Table 2.1 and 2.2. 
 
Table 2.1 Data set for pathway based survival analysis 
  




GSE19804  60  Affymetrix U133 Plus 2.0  
GSE10072  33  Affymetrix U133A  
GSE7670  27  Affymetrix U133A  
discovery*  Beer et al  442  Affymetrix U133A  
validation*  GSE8894  61  Affymetrix U133 Plus 2.0  
validation*  GSE3141  58  Affymetrix U133 Plus 2.0  
Colon  
nRef  
GSE37364  38  Affymetrix U133 Plus 2.0  
GSE8671  32  Affymetrix U133 Plus 2.0  
GSE9348  12  Affymetrix U133 Plus 2.0  
GSE4107  10  Affymetrix U133 Plus 2.0  
GSE22619  8  Affymetrix U133 Plus 2.0  
GSE22242  1  Affymetrix U133 Plus 2.0  
discovery*  GSE39582  443  Affymetrix U133 Plus 2.0  
validation*  GSE39582  123  Affymetrix U133 Plus 2.0  







Table 2.2 Data set for pathway based identification of cancer 




GSE19804  60/60  Affymetrix U133 Plus 2.0  
GSE10072  33/33  Affymetrix U133A  
GSE7670  27/27  Affymetrix U133A  
validation**  
GSE19188  18/15  Affymetrix U133 Plus 2.0  








2.2 Pathway data 
Information from gene sets representing biological pathways were 
obtained from REACTOME [88] which are also provided in the Molecular 
Signature Database [4]. I filtered out pathways where the number of genes was 
greater than 97. This criterion is arbitrary and was decided upon to avoid potential 
effects that were dependent on large gene set size. Out of 674 pathways that were 
originally from REACTOME, 583 pathways remained after filtering by the size of 
gene the set. 
 
2.3 Individualized pathway analysis using the nRef 
The aim of our approach is to identify altered pathways in an individual 
by making use of the nRef. A schematic diagram of our method of individualized 
pathway analysis is described at Figure 2.1 and the following sections describe 
each step. 
 
2.3.1 Data preprocessing & Gene level statistics 
Expression level was defined by using the robust multichip average [4]. 
For datasets using different microarrays, only those with probes in common from 
Affymetrix U133A to Affymetrix U133Plus 2.0 were used for further analysis. For 
individual tumor cases, we performed quantile normalization [89] after combining 
the single tumor microarray with all nRef samples. In cases of genes with multiple 
probes, gene expression level was summarized by averaging probe-level expression. 
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Individual tumor sample gene expression was stan-dardized using the mean and 
standard deviation of the reference. 
 
2.3.2 Pathway level statistics & Significance test  
I introduce five methods as candidates for iPAS. Each method is our 
modification of existing pathway analysis techniques, enabling us to test an 
individual tumor sample’s pathway aberrance by using the nRef. A summary is 
provided in table 2.3. 
 
Average Z 
Standardizing the gene expression by mean and standard deviation from 
data sets is often used in microarray analysis. A vector Z = (z1, z2, …, zn) denotes 
the expression status of a pathway where zi symbolize the standardized expression 
value of ith gene, where the number of genes belonging to the pathway is n. In 
typical settings, standardization is performed using the mean and standard 
deviation (s.d.) of a given data set, mostly the cancer only cohort data, thus |Z| /n 
indicates how much the given sample’s overall pathway gene expression deviates 
from the center of the cancer samples. I made the simple modification, Z’ = (z1’, 
z2’, …, zn), where zi’ is derived from mean and s.d. of the nRef. In this case, |Z’| /n 
gives the samples deviation from the nRef. I believe this modification is 
biologically valid because every cancer starts its malignancy from normal cell. 
Thus, the clinical characteristics of a single cancer can be captured by measuring 
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the difference of it against common characteristic of normal cells, which is 
represented by the nRef in our study.  
 
Fisher exact test 
I generated a 2 x 2 contingency table for a given pathway (S) and 
differentially expressed genes (D) for the test. For individualized interpretation, we 
define D by the ranking of z-value, which is standardized gene expression for the 
mean and s.d. of the nRef. For each individual sample, 5% (highest 2.5% and 
lowest 2.5%) of the total genes are defined as D. I applied a two-tailed test to detect 
alteration of pathways due to enrichment or depletion of differential genes. The 
result of this statistic can be interpreted as how many differentially expressed genes 
are enriched in the given pathway, where the expression difference refers to how 
much a patient’s gene expression deviates from the nRef. 
 
Gene set enrichment analysis (GSEA) 
I adopted the original version of GSEA proposed by Subramanian et al. 
[52]. Typically, inputs for GSEA are generated by testing whole cohort samples 
using phenotype label; t-statistic, correlation coefficients, and fold changes are 
usually used. In the personalized analysis setting, we use the z-value as an input for 
the GSEA algorithm, which is standardized gene expression by mean and s.d. of 
the nRef. The GSEA output Enrichment Score (ES) reflects the degree to which a 
gene set in the pathway is overrepresented at the extremes (low or high) of the 
entire ranked list of z-values from a single patient.  
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Non parametric quadratic test  
Gene expression in a pathway of a tumor sample is represented by vector 
Z = (z1, z2, …, zn), where zi standardized expression level of ith gene by mean and 
s.d. of the nRef, where n is the number of genes belonged to the pathway. A 
pathway characteristic of an individual patient’s pathway can be represented by the 
averaged Euclidean distance (Z
T
 Z/n). This gives the distance of a single patient 
from the center of the nRef due to the square of standardized expression difference, 
and thus does not reflect increased or decreased expression, only the extent of the 
expression difference. Genes in the pathway are usually functionally correlated, 
therefore use of the correlation structure of the normal samples may increase 
sensitivity enough to capture the aberrance of a single cancer case. I also consider 
the averaged Mahalanobis (Z
T
SZ/n) distance, that utilizes the covariance matrix 
calculated from the nRef. This value describes the statistical distance from the 
center of normal samples taking into account correlation among normal samples. 
The covariance matrix S is calculated for each pathway from the nRef. 
 
Significance can be obtained against the null distribution generated from 
normal samples. All the collected normal samples for the nRef are one by one 
compared to the nRef to yield statistics of the null distribution. A statistic from a 













Figure 2.1 Schematic description of individualized pathway analysis using accumulated normal data 
(nRef). An individual  tumor data is normalized with the nRef. Gene expression is standardized by 
mean and standard deviation of the nRef. iPAS is calculated from standardized gene expression values 



















Table 2.3. Pathway statistics for individualized pathway aberrance score (iPAS) 
 
  
Method Gene statistics Pathway statistics 
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2.4 Pathway based identification of rare mutation effect in cancer 
To evaluate functional impact of mutations on pathway, somatic mutation 
(WUSM mutation calling) and normalized gene expression (UNC Agilent 
G4502A_07, level 3) data of breast cancer is downloaded from TCGA web site 
[91]. The level 3 TCGA mRNA data provides gene level summary of mRNA 
expression, which is standardized by mean and standard deviation of entire data set. 
Samples having both mutation and gene expression data (n=513) are used for 
analysis. Missing gene expressions are replaced by zeros. 
Pathway gene sets are downloaded from molecular signature database. 
Total 543 gene sets from Biocarta, NCI cancer pathway [92] and KEGG pathway  
[93],[94] are used for our analysis. I also manually defined additional gene sets to 
assess rare mutations impact on pathways that include more than one drug target; 
we defined 16 receptor tyrosine kinase (RTK) genes which have more than one 
approved targeted drugs. Associated drug information is retrieved from Ingenuity 
SystemsTM [95]. For each of RTK genes, we expended the gene set by adding its 
first neighbors by adopting protein-protein interaction data in HipathDB [96]. 
Through this annotation process, we obtained gene sets representing 16 RTK 








Target  Drugs  First neighbors  
EGFR  
cetuximab, AEE 788, panitumumab, BMS-599626, ARRY-
334543, XL647, canertinib, gefitinib, HKI-272, PD 153035, 
lapatinib, vandetanib, erlotinib  
125  
PDGRFB  
dasatinib, sunitinib, pazopanib, axitinib, KRN-951, 
tandutinib, imatinib, sorafenib, becaplermin  
61  
ERBB2  
trastuzumab, BMS-599626, ARRY-334543, XL647, CP-
724,714, HKI-272, lapatinib, erlotinib  
59  
MET  crizotinib  55  
ERBB4  BMS-599626  44  
KIT  
dasatinib, sunitinib, pazopanib, KRN-951, OSI-930, 
telatinib, tandutinib, imatinib, sorafenib  
38  
FLT4  
sunitinib, pazopanib, CEP 7055, KRN-951, telatinib, 
sorafenib, vandetanib  
36  
PDGFRA  
sunitinib, pazopanib, axitinib, telatinib, imatinib, 
becaplermin  
35  
TEK  vandetanib  35  
RET  sunitinib, vandetanib  30  
FGFR1  pazopanib  29  
EPHA2  dasatinib  22  
FGFR3  pazopanib  18  
FLT3  CHIR-258, tandutinib, sorafenib, lestaurtinib, CGP 41251  14  
FGFR2  palifermin  13  
 




In our analysis, multiple rare mutations on the same gene are defined as a 
single mutation event. Our algorithm iteratively adds genes to mutation event while 
the mutation event makes significant difference between mutation having and non-
having sample group. Final output is a set of genes. The output can be interpreted 
as a set of rare mutations from a(several) gene(s) that have significant pathway 
level impact. Pseudo code description of our procedure is as follows. 
 
  
In the given pathway, define ‘gene list’ 
gene list : gene names in the given pathway  
 
for each gene in the ‘gene list’ 
while ( no more genes in the ‘gene list’ or 
            no more significant mutational event found ){ 
 
update : gene(s) name(s) to be considered as 
mutational event  
x: a vector containing pathway statistics of mutation event having 
patients 
y: a vector containing pathway statistics of mutation event non having 
group 
 
do t-test on x and y 
if( t-test p-value < fdr_threshold){ 
  add one more gene for mutation event 
} 
update fdr_threshold 




Chapter 3  
Results 
 
3.1 Capturing published survival related pathways 
To assess whether our method can sensitively detect pathway aberrances 
that are associated with a patient’s clinical outcome, a known survival pathway that 
showed strong association with patient survival from Beer’s data was tested. 
Bryant et al. [97] reported that the “cell cycle stimulatory” pathway of 51 genes is 
significantly associated with patient survival (Cox proportional-hazards model, P = 
0.000113). In that study, pathway gene expression was represented as an average of 
z-values, where the z-value indicates the standardized expression level, by the 
mean and s.d., of all cancer samples. The high-risk group was defined as those in 
which pathway expressions were greater than zero and the pathway showed poor 
prognostic outcome. The association was significant with or without adjusted 
clinical covariates, and thus the pathway alone is a strong indicator of cancer 
prognosis. This finding was also validated in the Japanese LUAD cohort (n = 87, 
survival data is not provided to public) in Bryant’s study. As studies have shown a 
clear association between the cell cycle pathway and cancer, in terms of driving 
cancer proliferation, we considered this pathway as a pathway that should be 
detected. All of the methods proposed as candidates for iPAS showed significant 
associations of the “cell cycle stimulatory” pathway from Beer’s data (Table 3.1). 
The same pathway analyzed using GSE8894 (n = 61) data yielded significant 
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associations in all proposed methods with the marginal exception of mahalanobis, 
(P = 0.0549). 
Prognostic gene expression signatures for stage II and III colon cancers 
have been reported in seven papers in, yielding 207 genes in total [90],[98-103]. 
The genes are enriched in 32 REACTOME pathways (FDR < 0.05, pathway size < 
96, Table 3.2). I assumed the 32 pathways were valid as ground truth to be 
identified and analyzed in the colon cancer dataset GSE39585 (stage II and III 
were only considered). Average Z provided best performer (sensitivity = 0.88) with 
28 pathways deemed as significant. GSEA, Fisher, Euclidean, Mahalanobis gave 
the following values, 0.78, 0.66, 0.06, 0.03, respectively. 
These results satisfied us that our approach captures the fundamental 











Data set Pathway Statistics Coef P value 
Beer (N = 432), Bryant et al., 
Overall survival 
Average Z* 0.37 0.00011 
Beer (N = 442) 
Overall survival 
Average Z** 0.62 0.00003 
Fisher 0.50 0.00068 
GSEA 0.65 0.00001 
Euclidean 0.65 0.00001 
Mahalanobis 0.67 0.00001 
GSE8894 (N = 61) 
Recurrent Free Survival 
Average Z** 0.90 0.01163 
Fisher 0.91 0.01076 
GSEA 0.78 0.02899 
Euclidean 0.87 0.01544 
Mahalanobis 0.68 0.05485 
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Table 3.2. Enriched pathways of 207 colorectal cancer survival genes 










REGULATION_OF_MITOTIC_CELL_CYCLE 85 5 0.0588 4.32E-05 4.16E-03 
SYNTHESIS_OF_DNA 92 5 0.0543 6.32E-05 4.73E-03 
REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC 49 4 0.0816 7.23E-05 4.87E-03 
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES 57 4 0.0702 1.31E-04 7.32E-03 




72 4 0.0556 3.24E-04 1.28E-02 
APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PRO
TEINS 
73 4 0.0548 3.41E-04 1.28E-02 
ANTIGEN_PROCESSING_CROSS_PRESENTATION 76 4 0.0526 3.98E-04 1.34E-02 
M_G1_TRANSITION 81 4 0.0494 5.07E-04 1.63E-02 
REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BI
ND_AU_RICH_ELEMENTS 
84 4 0.0476 5.82E-04 1.78E-02 
MITOTIC_PROMETAPHASE 87 4 0.046 6.64E-04 1.87E-02 
CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_C
DC6 
48 3 0.0625 1.34E-03 3.23E-02 
CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGE
NS_ENDOSOMES 
48 3 0.0625 1.34E-03 3.23E-02 
AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 51 3 0.0588 1.60E-03 3.26E-02 
P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT 51 3 0.0588 1.60E-03 3.26E-02 
SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 51 3 0.0588 1.60E-03 3.26E-02 
HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM 52 3 0.0577 1.69E-03 3.26E-02 
VIF_MEDIATED_DEGRADATION_OF_APOBEC3G 52 3 0.0577 1.69E-03 3.26E-02 
REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_IN_TC
_NER 
14 2 0.1429 1.77E-03 3.26E-02 
DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 53 3 0.0566 1.79E-03 3.26E-02 
CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPL
EX 
56 3 0.0536 2.09E-03 3.53E-02 
SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 56 3 0.0536 2.09E-03 3.53E-02 
P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 57 3 0.0526 2.20E-03 3.62E-02 
REGULATION_OF_APOPTOSIS 58 3 0.0517 2.32E-03 3.72E-02 
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 64 3 0.0469 3.07E-03 4.32E-02 
AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 64 3 0.0469 3.07E-03 4.32E-02 
INTERFERON_ALPHA_BETA_SIGNALING 64 3 0.0469 3.07E-03 4.32E-02 
ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 65 3 0.0462 3.20E-03 4.32E-02 
CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITIO
N 
65 3 0.0462 3.20E-03 4.32E-02 
SIGNALING_BY_WNT 65 3 0.0462 3.20E-03 4.32E-02 
ORC1_REMOVAL_FROM_CHROMATIN 67 3 0.0448 3.49E-03 4.61E-02 
NEPHRIN_INTERACTIONS 20 2 0.1 3.64E-03 4.71E-02 
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3.2 Proposed approach vs conventional approach 
To investigate which of the candidates for iPAS most robustly reflect 
phenotype association, we evaluated the proposed methods by determining whether 
survival associated pathways are validated in datasets never used for discovery 
using LUAD and colon cancer (LUAD: Beer’s set n=442 for discovery, 
GSE8894(n=61) GSE3141(n=58) for validation, colon cancer: GSE39582d (n=443) 
for discovery, GSE39582v(n=123) and GSE17536(n=109) for validation, logrank P 
< 0.05, comparing tumors in the top 50th percentile of aberrance scores to those in 
the bottom 50th percentile). Validation rates varied depending on the dataset and 
these were possibly affected by the small sample size compared to that of the 
discovery set. In these cases, we were not able to determine a superior method that 
outperformed the others (Table 3.3, Figure 3.1, 3.2). Average Z gave the highest 
validation rate in three out of four dataset with validation rates of GSE8894 (43.6%, 
92/211), GSE3141 (13.3%, 28/211) and GSE17536 (10.7%, 24/224). When 
validation rates from four datasets are averaged, Average Z gave the highest 
validation rate, (21.9%, Figure 3.3, blue bars). Pathways validated as significantly 
associated with patient survival for each cancer are listed in Table 3.4. I also 
investigated the validation rate of iPAS candidates under the conditions where the 
same data is not standardized by the nRef, but instead standardized by the mean 
and s.d. of the cohort dataset, which consists of only cancers (Figure 3.3, red bars). 
It is noteworthy that use of the nRef increased the validation rate for every iPAS 
candidate investigated. This implies that the strategy of using accumulated normal 
samples as a reference is beneficial in terms of pathway based survival analysis. 
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I further investigate the reason why the Ave Z generally performs better 
than the other methods in terms of validation rate. Thirty six survival related 
pathways were concordantly validated in two independent lung adenocarcinoma 
data sets. Visual inspections of the 36 pathways provide an insight about difference 
of its performance. Among 36 pathways, selected 5 pathways will be discussed. 
Each of 5 pathways is representing a pathway that is validated in two data sets by 
the method of Ave Z, GSEA, ED, MD and both of Ave Z and GSEA, respectively 
(Figure 3.5).  
A pathway ‘G1 S specific transcription’ is well explaining survival 
difference in three data sets by the methods of Ave Z and GSEA (Figure 3.6). The 
common feature of Ave Z and GSEA vs others (ED, MD, Fisher) is that Ave Z and 
GSEA use the information of ‘+’ or ‘-‘ of pathway statistics. This possibly explains 
in what circumstance if the methods perform better. If a true biology of a given 
pathways goes in one direction such as up-regulation of all member gene, or down-
regulation of all member gene, it is more appropriate to represent pathway 
characteristics with direction. In case true biology has a clear direction in the 
pathway function, ED and MD which performs square of standardized gene 
expression value, Fisher which provide test statistic of enrichment, do not represent 
the direction, thus might perform poorly.  
This is making sense in the specific case of ‘G1 S specific transcription’. 
In this pathway, almost all member genes are supposed to be up-regulated due to 
the tumurogenic signal. Figure 3.7 describe this phenomenon in detail. There are 
three distinguishing sample groups, down-regulated (S1), up-regulated (S3) and 
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intermediate (S2). Up-regulated sample subgroup (S3) has poor outcome due to the 
highly proliferating nature of this pathway. In both discovery data set and 
validation data set, methods using directionality Ave Z and GSEA are well 
representing the patient subgroup. However, in validation data set S3, other 
methods that do not utilize directionality information of gene expression perform 
poorly in prognostic prediction (Figure 3.6). This might be caused by different 
interpretations of genes which expressions are negatively regulated the way it 
usually work in cancer proliferation signal.  
Yellow circle in Figure 3.7 describe this case. In case Ave Z and GSEA, 
genes in the yellow circle can be interpreted as negative factors. The genes reduce 
the overall activity of the pathway in the interpretation of Ave Z and GSEA, which 
is concordant to biological facts.  However, in the interpretation of ED, MD and 
Fisher, the genes can be interpreted as positive factors, increasing overall extent of 
gene expression difference of the pathway, which is not concordant to biological 
facts. Figure 3.8 depicts the case GSEA performs better than the Ave Z in terms of 
validation. Both Ave Z and GSEA utilize gene expression directionality 
information, but the difference is considering the ranks pathway members genes in 
the whole genome context in GSEA analysis. Yellow circles at Figure 3.8 show 
discrepancy between Ave Z and GSEA.  
Some pathways validated in ED specific manner. Figure 3.9 describes this 
case. The ‘Cyclin A B1 asssociated events during G2 M transition’ pathway is 
consists of 15 genes. In tumorigenic situation, the pathway is generally up-
regulated in transcription level. Two genes CCNH and CCNA1 show down 
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regulated pattern while the other 13 genes in the pathway generally up-regulated. 
Actually, it has known that low expression of CCNH is activating cyclin dependent 
kinase activity, thus it is biologically proper that low expression of CCNH is 
associated with poor outcome in patient survival. In this pathway, contribution of 
CCNH is explained by its down regulation. Thus, methods using directionality of 
gene expression like Ave Z, GSEA miss-interpretate the contribution of CCNH by 
simply adding the negative value into overall sum (Ave Z) or little contribution of 
enrichment score while majority genes are up-regulated (GSEA). Unlike Ave Z and 
GSEA, methods ED and MD only consider the extent of gene expression changes, 
thus under expression of CCNH is also positively contribute to overall extent of 
gene expression change when these methods are considered. However, in this 
pathway, only ED is validated in two different data sets, while the MD is not. This 
might be the reason why the methodological difference between the two methods. 
One thing obvious is that not one method performs dominant against other 
method in all cases. Some pathway is consisted of up-regulated genes or down-
regulated genes. Some pathway is consisted of mixture of up and down regulated 
genes with biological meaning. It is important to know the characteristic of 








   
Discovery of survival related pathway (Beer’s data, n=442) 
 
Validation data set (GSE 8894, n=61) 
 
 
Validation data set (GSE3141, n=58) 
 
Figure 3.1 Validation rate of discovered survival related pathways in lung 
adenocarcinoma. Proposed approach using nRef (blue) vs. Conventional approach. 







































Discovery of survival related pathway (GSE39582d, n=443) 
 
Validation data set (GSE39582v, n=123) 
 
 
Validation data set (GSE39582v, n=177) 
 
Figure 3.2 Validation rate of discovered survival related pathways in colon cancer. 
Proposed approach using nRef (blue) vs. Conventional approach. 





































Figure 3.3 Averaged validation rate of discovered survival related pathway at four 
data sets. Proposed approach using nRef (blue) vs. Conventional approach that 














Figure 3.4 Validation rate of discovered survival related pathways ( # of pathways 
commonly validated at two data sets / # of survival related pathways discovered at 





























Method Beer  GSE8894 (A)  GSE3141 (B)  A ∩ B 
 
Beer GSE8894 (C)  GSE3141 (D)  C ∩ D 
LUAD 
Average Z 211 92 29 20 
 
203 79 33 16 
GSEA 199 75 25 14 
 
190 69 17 7 
Fisher 151 50 12 2 
 
41 1 3 0 
Euclidean 257 69 27 9 
 
53 2 3 0 
Mahalanobis  190 33 20 3 
 
96 5 6 1 
  
dGSE39582 vGSE39582 (A) GSE17536 (B) A ∩ B 
 
dGSE39582 vGSE39582 (C) GSE17536 (D) C ∩ D 
Colon 
Cancer 
Average Z 224 44 24 7 
 
238 42 15 3 
GSEA 184 35 8 2 
 
214 36 4 0 
Fisher 119 28 2 1 
 
28 1 0 0 
Euclidean 73 15 1 0 
 
71 0 1 0 
Mahalanobis  32 3 3 2 
 
106 1 4 1 
 
Table 3.3. Comparison of validation rates of survival related pathway using nRef vs. using entire cohort data 
* Cancer cohort data-based approach standardized gene expression values of an individual with the mean and s.d. of the entire cancer cohort data set where the 
sample originated from. This is counterpart experiment based on assumption what if an individual tumor sample is compared to many cancer data instead of many 
normal data. “Many cancer” data in this context is defined by cancer cohort dataset where an individual sample of interest is originated from. For example, if a tumor 
sample is one of member of GSE8894, the entire microarray data of GSE8894 is served for normalization and standardizing the expression value of the sample. 
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Result shows that using nRef-based approach generally increase the validation rate 
 
 
Beer GSE8894 GSE3141 
 
coef pval threshold coef pval threshold coef pval threshold 
ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 0.520099 0.000415 0.386737 1.21574 0.000892 0.861136 0.710268 0.046145 0.55635 
CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_ 0.42974 0.003513 0.247331 0.792707 0.027953 0.547786 0.716713 0.044535 0.213168 
DNA_STRAND_ELONGATION 0.71499 1.00E-06 1.274833 1.071312 0.003607 1.391335 0.716089 0.04458 1.193017 
FACILITATIVE_NA_INDEPENDENT_GLUCOSE_TRANSPORTERS 0.354506 0.01565 0.168691 0.763299 0.033131 -0.24277 1.184847 0.001134 -0.27284 
G1_S_SPECIFIC_TRANSCRIPTION 0.830124 0 0.890295 0.944739 0.00934 1.179604 0.702067 0.049373 0.167741 
G2_M_CHECKPOINTS 0.705606 2.00E-06 0.816311 0.904154 0.011586 1.161367 0.709231 0.04604 1.045875 
GLUCOSE_TRANSPORT 0.770402 0 0.678839 0.700776 0.049534 0.284518 0.913949 0.010858 -0.28531 
INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS 0.545955 0.000228 0.742698 0.841117 0.019373 0.558675 0.830168 0.019384 0.185536 
M_G1_TRANSITION 0.552641 0.000178 0.513903 1.032637 0.00431 0.877324 0.733152 0.039056 0.637421 
METABOLISM_OF_NUCLEOTIDES 0.415754 0.004697 0.674579 0.987276 0.006085 0.720526 0.701953 0.048824 0.607988 
PHOSPHORYLATION_OF_THE_APC_C 0.688238 3.00E-06 0.487527 0.897167 0.013935 0.775273 0.743429 0.035953 0.891884 
POL_SWITCHING 0.765461 0 0.759954 1.298079 0.000486 1.169592 0.742413 0.038171 0.909319 
PROCESSING_OF_CAPPED_INTRONLESS_PRE_MRNA 0.44213 0.002712 0.238756 1.199786 0.001042 0.637821 0.715653 0.043672 0.673775 
PYRIMIDINE_METABOLISM 0.496914 0.000737 0.670047 0.865313 0.015118 0.505466 0.76726 0.030959 0.15402 
RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES 0.591678 6.10E-05 0.478313 0.850128 0.01803 1.178261 0.740686 0.038929 0.960324 
REGULATION_OF_MITOTIC_CELL_CYCLE 0.657655 9.00E-06 0.47527 0.888198 0.013234 0.760152 0.74365 0.036574 0.567474 
REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_IN_TC_NER 0.761335 0 1.102294 1.298079 0.000486 1.339255 0.906748 0.011015 1.208045 
SYNTHESIS_AND_INTERCONVERSION_OF_NUCLEOTIDE_DI_AND_TRIPHOSPHA 0.495164 0.000785 0.81846 0.731939 0.040875 1.201097 0.767719 0.032327 1.280663 
SYNTHESIS_OF_DNA 0.575068 9.80E-05 0.589823 1.032637 0.00431 0.963818 0.733152 0.039056 0.718498 
UNWINDING_OF_DNA 0.664002 7.00E-06 1.968073 0.884732 0.013615 1.719352 0.777411 0.028587 1.531343 
 
Table 3.4.  Pathways associated with LUAD survival validated in two independent datasets  






Figure 3.5 Selected pathway for visual inspection of gene level expression and 










Figure 3.6 Pathway based survival analysis (Reactome G1 S specific transcription) 
at discovery set (first row, Beer data set) and two independent validation set 
(second and third row, GSE8894 and GSE3141 respectively). AveZ and GSEA 
































Figure 3.7 Gene and pathway level mRNA level expression profile of “G S1 specific transcription” pathway. The yellow circles indicate 







Figure 3.8 Gene and pathway level mRNA level expression profile of “Regulation of hypoxia inducible factor HIF by oxygen” pathway. 










Figure 3.9 Gene and pathway level mRNA level expression profile of “Cyclin A B1 asssociated events during G2 M transition” pathway. 




3.3 Discovery of clinical importance 
Cluster analysis of using Average Z as the iPAS method on Beer’s data 
identified 12 pathway clusters (denoted by 1~12 in Figure 3.10) and 3 sample 
clusters (S2~S4, S1 is from the nRef, Figure 3.2). Sample clusters S2 and S4 
represent well the differentiation status of LUAD (Fisher exact test, P<4.65*10-15). 
Well-differentiated adenocarcinoma resembles the normal glandular structure; 
therefore, it is a reasonable result that cluster S2 is close to the nRef. The survival 
outcome of S2 and S4 are significantly different (P<0.0028), and this assures us 
that unbiased clustering based iPAS has enough sensitivity to capture clinically 
important associations. This finding is concordant with prior knowledge that well-
differentiated LUAD patients are likely to have better prognosis [104]. Pathway 
cluster P9 is distinguished as commonly up-regulated in tumor samples. The 
pathways are tRNA aminoacylation, amino acid or purine synthesis, DNA 
elongation, and the extension of telomeres.  
Unbiased pathway based clustering of colon cancer data also captures 
clinically important associations by revealing sample clusters that are survival 
related (S2 and S3, P = 0.0037, Figure 3.11). It is important to note that iPAS is not 
only sensitive enough to identify clinically meaningful substructure of patients, but 
also reveals common characteristic of cancers at the same time. For example, 
pathways commonly up- or down-regulated in all cancer samples, for example, P9 
or P2, would have not been discovered if the analysis had been performed by a 





Figure 3.10 Clustered iPAS of lung adenocarcinoma dataset. Pathways (n = 583) 
and samples (n = 442) are clustered according to iPAS. Normal samples are 
clustered at left (S1). Tumors (S2~S4) deviate from normal in both up and down 
regulated directions (darker red and blue, respectively). Sample clusters are well 
representing histopathological differentiation status (S2 : for well-differntiated lung 









Figure 3.11 Unbiased clustering using iPAS of colon cancer dataset. Pathways (n = 
583) and samples (n = 443) are clustered according to iPAS (Average Z). Normal 
samples are clustered at left (S1). Tumors (S2~S4) deviate from normal, being both 
up- and down-regulated, (darker red and blue, respectively). Sample clusters 
represent well the overall survival of patients (P = 0.0038). There were no survival 












Figure 3.12 nRef-based approach (left) and the conventional approach (right) provide different 
interpretations. The same data was processed with two different approaches. The approach using 
nRef can identify globally up- or down-regulated pathways in cancer samples can also identify 
variant pathways across cancer samples. The conventional approach considers all cancer samples as a 
cohort, and then normalizes all of the samples together. Pathway score is represented in the 
conventional approach by averaging standardized gene expression values, where the mean and 
standard deviation of all cancer samples are used for standardization. Because an individual samples’ 
pathway statistic is affected by the context of other cancer samples, pathways commonly up- or 




3.4 Pathway based identification of cancer 
Cancer develops unique mechanisms for malignancy. Therefore, it is 
reasonable to believe that identifying the unique molecular aberrances of cancer 
will aid in cancer diagnosis. Our empirical study of iPAS-based clustering of 
LUAD revealed several pathways commonly up- or down-regulated in all of the 
cancer samples. Further analysis was performed to determine if iPAS could be 
successfully used in the accurate identification of cancer. I tested this in a simple 
unsupervised way by judging whether an unknown sample is significantly different 
against the nRef, as a tumor, if not as normal. I performed a 5-fold cross validation 
one hundred times with the LUAD data set, which consisted of 120 cancers and 
120 normal samples. Microarray data from the normal samples was randomly 
divided into five groups, and four of the five served as the reference groups. The 
remaining group was used as the test for the true normal set. The same amount of 
data was randomly picked from the cancer microarray data set and served as the 
true cancer set. I considered 583 pathways in REACTOME, giving a total of 
293,500 (583 pathways × 5 fold × 100 repeats) AUCs and accuracy values. I 
averaged AUCs and accuracies from the five candidate methods for iPAS and used 
this as a representative AUC and accuracy of a given pathway. 
By ranking the pathways by AUC, top pathways that marked averagely 
high performance by all iPAS candidates, are listed. The “amino acid synthesis and 
interconversion & transamination” pathway showed the highest classification 
performance. Unsurpri-singly, this pathway was one of the commonly up-regulated 
path-ways in the analysis of the Beer’s data (Figure 3.5, pathway cluster P9). 
75 
 
Among the tested iPAS candidates for this pathway, Mahala-nobis yielded the 
highest AUC (0.980), while Average Z gave 0.936 and Fisher’s exact test gave the 
lowest value, (0.914) (Table 3.5). The standardized gene expression pattern for this 
pathway differed between tumor and normal. Many of the genes deviated from 
mean of the nRef, by more than two orders of sigma, contributing to its best 
performance out of all iPAS candidate methods, including ORA method like 
Fisher’s exact test (Figure 3.13). 
The “amino acid synthesis and interconversion & transamination” 
pathway consists of 17 genes involved in three major reactions, as it is described at 
REACTOME. The pathways are responsible for; (1) synthesis of three amino acids 
(aspartate, asparagine, glutamate), (2) the synthesis of glucose under fasting 
conditions by utilizing carbon atoms from these four amino acids, (3) conversion of 
amino acids to their corresponding alpha-keto acids, coupled to their conversion to 
glutamate, which is the first step in the catabolism of most amino acids. This 
function makes sense in terms of the “glutamine addiction” of cancer cells. The 
nutrients glucose and glutamine are specifically required by cancer cells as 
metabolites for growth and for production of ATP [105]. Myc and p53 have been 
revealed to be associated with this “addiction” by up-regulating glutamine 
synthesis in cancer cells. Thus, our finding is in accordance with prior knowledge 
regarding the up-regulation of glutamine synthetase.  
I further validated our findings with an independent set that were not used 
in the discovery set. I collected two more LUAD gene expression data sets with 
normal data at GEO (GSE19188, GSE31547). Aggregated data sets of 48 
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microarrays from tumor tissues, and 35 microarrays from normal tissues were used 
for independent validation. The pathway was also altered in a cancer specific way 
in a validation set yielding an AUC of 0.982 by Mahalanobis-based iPAS (Figure 
3.14, validation 1). I also assessed the same validation set in a different manner by 
using the nRef from the discovery set. Normal sample microarrays from the 
discovery sets (GSE10082, GSE7670, GSE10072) served as the nRef to classify 
samples in the independent validation set. The resulting AUC was 0.982 by the 
Mahalanobis method (Figure 3.14, validation 2). In our experiments using LUAD 
samples, the Mahalanobis distance, which used a pre-calculated covariance matrix 
from the ‘nRef,’ gave the best performance. Based on these results, we conclude 
that iPAS using Mahalanobis is best method to use in the pathway- based 
identification of cancer.  
The biological role of this identified pathway is to supply nutrients and 
energy to cancer cells. This may be the reason why this pathway is universally 
aberrant in all the LUAD samples we assessed. I also investigated other cancers, if 
this pathway is useful to identify cancer. I collected microarray data of 156 breast 
cancers and 114 breast normals, 149 colon cancers and 145 colon normals, 151 
ovarian cancers and 120 ovarian normals. Pathway based identification of cancer 
by using “Aminoacid synthesis and interconversion” pathway results AUC of 0.921 
at breast cancer, 0.900 at colon cancer, 0.953 at ovarian cancer (Figure 3.15). Our 
analysis of this pathway in other cancer types demonstrated less of a role for this 
pathway. This suggests that the biological role of this pathway in cancer is more 
LUAD specific than other cancers.  
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I believe that the common disruption of this pathway is a novel discovery 
as this pathway, consisting of 17 genes, has not been reported as an indicator of 
LUAD in any of the studies we acquired data sets from (GSE10082, GSE7670, 












Pathway name (REACTOME) Aver Z  GSEA  Fisher  ED* MD* Mean  
AMINO_ACID_SYNTHESIS_AND_INTERCONVERS
ION_TRANSAMINATION 
0.936  0.950  0.914  0.958  0.980  0.947  
UNWINDING_OF_DNA 0.937  0.942  0.833  0.920  0.937  0.914  
O_LINKED_GLYCOSYLATION_OF_MUCINS 0.925  0.939  0.833  0.955  0.910  0.912  
SYNTHESIS_AND_INTERCONVERSION_OF_NUCL
EOTIDE_DI_AND_TRIPHOSPHA 
0.941  0.953  0.738  0.932  0.946  0.902  
APC_CDC20_MEDIATED_DEGRADATION_OF_NE
K2A 
0.885  0.906  0.799  0.945  0.948  0.897  
PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_
BIOSYNTHESIS 
0.905  0.915  0.820  0.921  0.912  0.895  
PURINE_METABOLISM 0.915  0.918  0.729  0.945  0.936  0.889  
DNA_STRAND_ELONGATION 0.889  0.920  0.783  0.930  0.916  0.888  
DEGRADATION_OF_THE_EXTRACELLULAR_MA
TRIX 
0.839  0.906  0.804  0.964  0.918  0.886  
G1_S_SPECIFIC_TRANSCRIPTION 0.837  0.876  0.813  0.945  0.957  0.886  
G0_AND_EARLY_G1 0.873  0.888  0.767  0.948  0.948  0.885  
KINESINS 0.862  0.878  0.809  0.928  0.938  0.883  
GLUCONEOGENESIS 0.890  0.910  0.783  0.903  0.902  0.877  
ACTIVATION_OF_THE_PRE_REPLICATIVE_COMP
LEX 
0.892  0.908  0.737  0.909  0.918  0.873  
E2F_MEDIATED_REGULATION_OF_DNA_REPLIC
ATION 
0.903  0.903  0.725  0.925  0.893  0.870  
DEPOSITION_OF_NEW_CENPA_CONTAINING_NU
CLEOSOMES_AT_THE_CENTROM 
0.911  0.930  0.828  0.966  0.706  0.868  
EXTENSION_OF_TELOMERES 0.840  0.889  0.762  0.913  0.926  0.866  
CELL_CYCLE 0.894  0.922  0.766  0.955  0.780  0.863  
INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_
OF_APC_C_REQUIRED_FOR_ 
0.852  0.881  0.745  0.888  0.951  0.863  
 
Table 3.5. AUC of pathway-based classification of tumor sample via different pathway 









2.3.1 Comparison of CpG depletion measures and fractional methylation 
level 
 
 Recently, the genome-wide DNA methylation of several eukaryotic 
organisms was quantified [27]. From the quantified methylation fraction of genes 
in those organisms, significant negative correlation was shown between the CpG 
depletion measures (CpG O/E and Pearson’s residual) and the methylation 
fractions in Apis melifera and Ciona intestinalis (Table 2.1) in this thesis. The CpG 
O/E and Pearson’s residual also significantly positively correlated with each other 
(Table 2.1). When the methylation fraction was log-transformed, the correlations 
were increased (Table 2.1). Before the log transformation the zero values in 
methylation fraction were removed for calculating the more accurate correlation. 
The correlation between methylation fraction and Pearson’s residual were similar 
to those of CpG O/E. The correlations of log-transformed data Pearson’s residual 








Figure 3.13 Expression pattern of genes in the pathway. Each line represents 
sample. (Grey: Normal, Red: Tumor). Dashed line represents expression value 















Figure 3.14 Performance of classification of cancer by ‘Amino acid synthesis 
and interconversion transamination’. AUC of 0.980 has marked in discovery set, 
independent validation set results AUC of 0.982 (validation 1: normal samples 
in validation set served as reference) and 0.982 (validation 2: normal samples in 






Figure 3.15 Identification of cancer by the ‘amino acid synthesis and 
interconversion transamination’ pathway. The pathway identified in lung 
adenocarcinoma was investigated to determine its usefulness in the identification of 







Table 3.6. Identification of cancer by “amino acid synthesis and interconversion 
transamination” pathway in other cancer types. The pathway shows decreased 
performance in the identification of cancer in samples from other cancer types, 






Average Z GSEA Fisher Euclidean Mahalanobis 
Accuracy  
BC 0.689 0.689 0.467 0.737 0.863 
CC 0.776 0.738 0.667 0.544 0.738 
OC 0.424 0.443 0.446 0.458 0.838 
AUC  
BC 0.790 0.827 0.772 0.864 0.921 
CC 0.844 0.823 0.848 0.837 0.900 
OC 0.528 0.542 0.547 0.645 0.953 
 
 
BC: Breast cancer (Test normal: 114, Test tumor: 156) 
CC: Colon cancer (Test normal: 145, Test tumor: 149) 






3.5 Pathway based identification of rare mutation effect in cancer 
Mutation information is getting more useful for stratified medicine. For 
example, KRAS mutation is a test recommended to targeted drugs of colon cancer 
therapy [106], EGFR activation mutations and resistant mutations for targeted 
therapy for non small cell lung cancers [107]. Only a few mutations are known to 
be clinically actionable, most of less frequent mutations are remained to be 
understood.  
In conjunction with iPAS, we performed integrated analysis of mutation 
and pathway level gene expression to discover a combination of rare mutations that 
causes pathway level gene expression changes. Assuming combination of 
functionally related rare mutations can influence the pathway of mRNA expression, 
we consider multiple rare mutations to be counted as a single mutation event. At 
the first step of our analysis, we assess if pathway level mRNA expression is 
significantly different between the group of with mutation and without mutation. If 
it is different, we add another mutation sites to be counted as a single mutational 
event, then assess if the new event can still differentiate pathway level mRNA 
expression. I iterate this procedure until no more rare mutation can be added into 
mutational event under the certain significance threshold for pathway level gene 
expression difference. The output can biologically be interpreted as a set of 
mutations that influence the pathway level gene expression, thus the mutations can 
be considered functional in cancer, further be prioritized as cancer drivers. 
To assess whether our method can sensitively capture the impact of 
mutational event to the pathway level gene expression, we analyzed breast cancer 
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data set from TCGA having paired somatic mutation and expression data (n=513). 
Mutational event of single gene is described at Figure 3.16. Mutations that changes 
gene expression level of the mutated genes (FDR q-value < 0.1) are shown in blue. 
Mutated genes those gene level expression are changed, but pathway level mRNA 
expression are changed (FDR q-value < 0.1) are shown in red. In the latter case, 
there were three mutated genes causing pathway level difference in 24 pathways. 
The three genes are TP53 (187 are mutated out of 513 samples, 36.4%), PIK3CA 
(173/513, 33.7%), RB1 (11/513, 2.1%), previously implicated in breast cancer. 
It is noteworthy that the pathway of the three genes  are addressed as 
crucial by the original research [91]. In the TCGA [91], three pathways (PI3K, 
TP53 and RB pathways) are considered as representative pathways for breast 
cancer, and addressed its functional status with protein level phosphorylation. In 
our analysis, we discovered mutations on TP53, PIK3CA and RB1 have significant 
impact on pathways, without any prior knowledge, but by analyzing the mutation 
and mRNA expression data. This indirectly proves that our approach is sensitive 
enough to capture the important biological features; thus it can be properly 









Figure 3.16 Single gene’s mutational influence on mRNA expression at gene 
level (X axis) and pathway level (Y axis). X : averaged gene expression 
difference of mutation having group minus non having group). Y : averaged 
pathway level difference of mutation having group minus non-having group). Z : 
-log10p score, where p is from t-test of pathway statistics between mutation 
having group vs non-having group. Red : mutational event where its influence on 
pathway level is significant (FDR q-value<0.1). Blue dots : mutational event its 
influence on gene level is significant (FDR q-value<0.1) but not significant at 




Twenty four pathways showed differential mRNA expression between 
groups with and without mutations of TP53, PIK3CA and RB1 mutations (Figure 
3.17). TP53 and PIK3CA are not mutually exclusive at the observation of TCGA 
breast cancer data, which is concordant to the previous report [40]. Heatmap 
visualization of unsupervised clustering of pathway level characteristics shows 
distinguishing subgroup pattern between “TP53 mutated and PIK3CA non-mutated 
samples enriched” subgroup (C and D) and “TP53 non-mutated and PIK3CA 
mutated samples enriched” subgroup (A and B). This characteristic might be 
explained based on to previous findings that TP53 gene product regulates PIK3CA 
in a transcriptional level. 
Astanehe et al., [109] demonstrated that direct binding of TP53 reduces 
the expression of PIK3CA, thus decreases the expression of PIK3CA expression. In 
our analysis, sample cluster of C and D, representing un-mutated samples on 
PIK3CA keeps this mRNA deregulation functionality of PIK3CA, showing 
pathway level down-regulation in PIK3CA related pathway cluster P1. Unlike 
sample cluster C and D, PIK3CA mutation enriched sample cluster of A and B 
might have TP53 mediated regulation of PIK3CA gene product, showing pathway 
level up-regulation in the pathways P1.   
Mutations on RB1 are enriched at sample group C and D, showing a 
tendency that it is coupled to TP53 mutation status. Subgroup having mutations on 
both of RB1 and TP53 has unfavourable outcome when it is compared to the others. 
The observation is concordant to the known biological knowledge that breast 
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cancer subpopulation having retained activity of the major tumor suppressors RB1 

























Figure 3.17 Normalized heatmap description of top pathway influencing mutations (PIK3CA, TP53 
and RB1, q-value < 0.1). Column side bar describes mutation events on RB1, TP53, PIK3CA with 




In the analysis of impact of single gene mutation into the pathway, rare 
mutations having less than 11 mutated samples were not reported as significant at 
q-value < 0.1. To further assess combinatorial rare mutation genes in the pathway 
level mRNA expression, we iteratively combine mutated genes so that multiple 
mutational events can be considered  on multiple genes into one mutational event 
increasing the sample size of group with mutations. Mutations reported as 
significant in the single gene mutation analysis is discarded in the combinatorial 
iteration, to avoid its strong impact and hopefully to find additive impact of rare 
mutations only. 
Through our additive combination of rare mutations into one event, we 
have found 19 mutation events affecting on pathway level at the cut of FDR q-
value < 0.25. Figure 3.18 depicts the relationship of pathway level mRNA 
expression difference between groups with and without mutational events  (X 
axis), number of samples having mutation events (Y axis), and the significance of 
impact of the mutational event (Z axis).   
Among 15,819 genes with somatic mutations reported in 513 breast 
cancer samples, 63 genes were  shown to have pathway level impact when it is 
combinatorially considered as a mutational event. Gene ontology analysis using 
g:Profiler [110,111] showed significant functional enrichment of these genes into 
cancer related biological processes like ‘cell proliferation (p-value = 1.17e-07)’, 
‘cellular component organization or biogenesis (p-value = 6.45e-15)’, ‘response to 
stimulus (p-value = 1.7e-13)’, ‘cell cycle (p-value = 2.16e-19)’ and ‘developmental 
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process (p-value = ‘1.3e-14)’. This is a supportive information that our method not 
just coincidentally picked rare mutation genes with pathway impact, but sensitively 
reveal the additive impact of rare mutations in the context of pathway level mRNA 
expression change. 
Based on these results, we suggest the 63 genes along with 3 genes that 
showed single gene’s mutational influence on pathways as  potential tumor driver 
mutations, having more functional importance than the other 15,750 somatic 
mutations. Table 3.7 provides mutational events that have shown pathway level 
impact in the combinatorial summary of mutation event among the 63 genes. 
I further investigated pathway level impact of somatic mutations against 
gene networks having actionable drugs. Among 19 receptor tyrosine kinase related 
pathways, three pathways have shown pathway level difference with two mutation 
event (Table 3.8). 
LYN is a member src kinase superfamily and is known to be involved in 
the regulation of cell activation. Recent publication [112] addressed SH2 domain 
missense mutation D197Y at breast cancer is functional. Over expression of 
D197Y is more potent than wild type LYN at inducing signaling cascade, rendering 
the treatment of ER downreguatlor fulvestrant or PI3K inhibitor BKM120 less 
effective. This indicates LYN may play a role for ER+ breast cancer acquiring 
hormone-independent growth. Two LYN mutations in our discovery for RTK 
pathway related mutation event were located SH2 domain (E159K, K188N), they 
may be considered to have similar contribution to D197Y.  
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NCK1 is downstream of signal cascade of LYN. Its major function is 
activating actin cytoskeleton reorganization. There is no evidence how  LYN and 
NCK1 regulate the transcription level of PDGFR pathways. Our observation 
indicates that the group with either mutation of  the two genes has lower level of 
gene expression in the PDGFR pathway than the group without mutations. 
Among mutation event of 16 samples either of three genes (PIK3R1, 
PIK3CD and GRB2), PIK3R1 is the most frequent (# of event samples : 14). Most 
of 14 mutations clustered in the PIK3CA interaction domain. BKM120 and GDC-
0941 are the suggested drugs for patients having mutation at PIK3R1 sites [91]. 
PIK3R1, PIK3CD and GRB2 are all interacting together, having mutation on these 
genes can cause similar impact on downstream pathways.  
In summary of receptor tyrosine kinase pathways, we additionally 
discovered two mutational events that have significant pathway level mRNA 
change. Literature survey on discovered mutations also revealed that the mutations 
are potential drug target. This is another supporting evidence that our method can 
sensitively detect functional rare mutations, in other words, measuring pathway 




























Figure 3.18 Multiple gene’s mutational influence on mRNA expressino at 
pathway level (X axis). X : averaged pathway level difference of mutation 
having gorup minus non-having group. Y : number of samples having 
summarized multi-gene mutation event. Z : -log10p score, where p is from t-
test of pathway statistics between mutation event having group vs non-having 
group. Red : mutational event where its influence on pathway level is 




























Table 3.7. List of multiple gene’s mutation events having impact on pathways 
 
Pathway  




t-stat  q-value*  
KEGG_GLIOMA  PIK3CB,HRAS  5  12.587  0.000  
KEGG_MELANOMA  PIK3CB,BRAF  7  10.302  0.000  
PID_CDC42  CDH1,MAP3K1  70  -5.244  0.000  
PID_TRAIL  RIPK1,MAPK3  6  9.624  0.000  
BIOCARTA_PPARA  NCOR1,EHHADH  21  -4.562  0.007  
PID_A6B1_A6B4_INTEGRIN  COL17A1,GRB2  6  -6.239  0.009  
BIOCARTA_MTOR  TSC1,TSC2  7  -5.081  0.010  
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYT
ES  
ITPR3,RPS6KA3  7  6.174  0.014  
PID_CERAMIDE  MAP2K4,AKT1,RIPK1  35  4.803  0.017  
SA_PTEN  AKT3,BPNT1  5  -6.573  0.018  
ST_FAS_SIGNALING  MAP3K1,EZR  42  -3.727  0.029  
PID_EPHBFWDPATHWAY  EPHB1,EFNB1  9  -4.848  0.032  




49  -5.564  0.074  
















11  -11.81  0.242  
 
 
Table 3.8. List of multiple gene’s mutation events having impact on drug target centric 
pathways 
 




PDGFRB_neighbors LYN, NCK1 5 -8.3139 0.005 






Chapter 4. Summary and Conclusion 
 
In this thesis, we have proposed personalized extensions to ORA- and 
FCS-based pathway analysis by introducing the concept of comparing an 
individual tumor to many normal samples. Exploratory analyses of our methods 
with previously published survival pathway signatures reproduced the correct 
survival outcomes. I have also demonstrated that using nRef improves the 
validation rate. Unbiased clustering with individualized pathway aberrance scores 
revealed sample clustering, which is indicative of the cancer differentiation status 
of LUAD and of different survival outcomes. Clustering also identifies pathway 
characteristics from patients displaying common up- or down-regulations and sub-
group specific deregulations.  
Pathways that are commonly deregulated across all cancer patients may 
be useful in identifying cancer from unknown samples. I explored the pathway-
based identification of cancer with “amino acid synthesis and interconversion 
transamination” pathway, which is commonly up-regulated in LUAD patients. 
Validation using independent data sets demonstrated that this pathway is useful in 
classifying LUAD and normal lung samples. 
Based on our results, we conclude that individualized pathway scores 
using nRef can provide a sensitive measure of a patient’s clinical features and can 
be useful for identifying cancer.  
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In our empirical study, Average Z performed best in highlighting pathway 
aberrance and in further revealing clinical importance. It had the best statistical 
power when identifying a previously known survival related pathway and the best 
averaged validation rate of survival related pathways for LUAD and colon cancer. 
In the pathway-based identification of cancer, the Mahalanobis method performed 
best.  
Additionally, we developed an approach that assesses mutational impact 
on pathway level mRNA expression. I suggest combinatorial summary of 
mutational events. I have demonstrated that the approach sensitively discovers 
important mutations that have been known to have pathway level impact. Important 
mutations that cause deregulation of representative breast cancer pathways reported 
by previous study have been captured..  
Combinatorial mutation summary found 63 genes that showed pathway 
level difference between groups with and without mutation events. Based on 
pathway level impact analysis result, we suggested functional importance of 
somatic mutations on the 63 genes is bigger than the others. I also investigated 
impact of rare mutations on drug target pathways; we found two mutation events 
that  consisted of two  and three genes, respectively. Two of total five mutations 
were mentioned as potential drug target in the literature, indirectly supporting that 
our approach is useful to prioritize druggable mutations.  
Due to the innovation of next generation sequencing technology, more 
cancer patients’ genome and transcriptome are expected to be available. 
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Accumulation of data will enable more accurate estimation of functional impact of 
rare mutations.  
There are three challenging issues further to be investigated as an 
extension of this work. Firstly, determining platform dependency should be 
considered. I have applied our approach into data sets from the same platforms. To 
address the pathway level aberrance of a single cancer sample accumulated normal 
data from the same platform to the cancer case must be collected. Addressing if 
different platform data (e.g next generation sequencing data of cancer case against 
microarray data of normals) is interpretable is next challenge. Secondly, regarding 
the methodology, extending our approach by considering pathway topology (PT) is 
considerable. Impact factor analysis introduced at chapter 1 and appendix considers 
the impact of functional neighbors [66,67]. Thirdly, extending our philosophy to 
multiple omics data is considerable. Although we have demonstrated the concept of 
our approach in mRNA level data only, it is not limited to a single layered omics 
data. In our methods, gene level statistics standardized to represent how much a 
single cancer sample data is deviated from accumulated normal reference data. 
This philosophy can be implemented in multiple omics data by various statistical 
methods such as combining p-values or summarized statistics [113]. 
An important clinical aspect of our methods is that it enables the 
interpretation of a cancer case in a single patient, even if matched normal tissue 
data from the same individual is unavailable. Accumulated information of normal 
tissues from a data repository will take the place of data unavailable for a specific 
individual. As the data repository is growing rapidly, it is expected that more “nRef” 
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data will be available for many diseases in the near future. I hope that our proposed 
approach can help in the personalized interpretation of tumor data and can be a 
useful tool in the upcoming era of data-based personalized medicine.  
I hope that our proposed approach can be used to discover mutations 
having functional impact, thus further to prioritize mutations for the consideration 










The code for this study is available at 
http://bibs.snu.ac.kr/ipas 
 
A quick start instruction is as follows. 
 




(make sure to unzip the folder bgDistribution) 
Execute R and set the working directory to the unzipped folder of downloaded 
codes. 
Run the following codes. 
 
/* 
tumorFile = "Beer_10samples.txt" 
refFile = "LUAD_nREF.txt" 
pathwayListFile= "reactome.txt" 
whoami = "testRun2" 
runMode = "nRef" 
            
sourcePath = "iPAS_library.r" 
source(sourcePath ) 
bgDistributionPath = "./bgDistribution" 
 
iPAS( tumorFile, refFile, pathwayListFile, whoami, runMode, 









Impact Factor Analysis 
Impact Factor (IF) analysis [66, 67] combines both ORA and FCS 
approach, while accounting for the topology of the pathway. IF analysis computes 
Perturbation Factor (PF) for each gene in each pathway, which is a gene-level 
statistic, as follows 
 
In Eq. 1, the rst term, ΔF(gi), represents the signed normalized measured 
expression change (i.e.,fold change) of the gene gi. The second term in Eq. 1 
accounts for the topology of the pathway, where gene gj is upstream of gene gi. In 
the second term, ji represents the type and strength of interaction between gi and gj . 
If gj activates gi, ji = 1, and if gj inhibits gi, ji = -1. Note that the PF of the upstream 
gene gj is normalized by the number of downstream genes it interacts with, Nds(gi). 
The second term is repeated for every gene gj that is upstream of gene gi. 
 
After computing PF for each gene, pathway-level statistic, Impact Factor 





In Eq. 2, the first term captures the significance of the given pathway Pi as 
provided by ORA, where pi corresponds to the probability of obtaining a value of 
the statistic used at least as extreme as the one observed when the null hypothesis is 
true. Because IF should be large for severely impacted pathways (i.e., small p-








the exponential scale of the p-values to a linear scale in order to keep the model 
linear. The second term sums up the values of the PFs for all genes g on the given 
pathway Pi, and is normalized by the number of differentially expressed genes on 
the given pathway Pi.  
Note that Eq. 1 essentially describes the perturbation factor PF for a gene 
gi as a linear function of the perturbation factors of all genes in a given pathway. 
Therefore, the set of all equations defining the PFs for all genes in a given pathway 
Pi form a system of simultaneous equations. Expanding and re-arranging Equation 





After computing the PFs of all genes in a given pathway as the solution of 
this linear system, Eq. 2 is used to calculate the impact factor of each pathway. The 
impact factor of each pathway is then used as a score to assess the impact of a 
given gene expression data set on all pathways (the higher the impact factor the 
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유전자 네트웍의 이상을 탐지하는 것은 질병의 기작을 이해하고 
나아가 개인의 유전자 결함에 맞춤 치료를 선정하는 일에 중요하다. 
현재 존재하는 유전자 조절/생체 대사 경로 분석 알고리즘은 대부분 
정상과 대조군 집단에서의 차이를 판별하는 데에 초점이 맞추어져 있다. 
이러한 방법은 한 개인에 초점을 맞추어 분석을 하는 용도로는 적합하지 
못하다. 
한 개인의 유전자 네트웍의 이상을 분석함에 있어 가장 
이상적인 방법은 같은 환자의 정상 조직과 질병 조직의 정보를 비교하는 
것이다. 하지만, 임상적인 이유에서 환자의 정상 조직의 정보는 항상 
가용한 것은 아니다. 정상 조직을 채취 하는 것은 임상적인 위험이 
따르며, 특별하고 명확한 이유가 없는 한 권장되지 않는다. 따라서 질병 
시료의 개인 맞춤 분석에 있어서, 같은 사람의 정상 조직 정보는 
가용하지 않은 경우가 많다. 본 논문에서는 개인 분석이라는 측면과 
해당 환자의 정상 조직 정보가 가용하지 않을 때 유전자 네트웍을 
분석하는 것에 초점을 맞추었다. 본 논문의 방법의 철학은 한 사람의 암 
환자 유전자 정보를 많은 수의 집적된 정상 조직의 유전자 정보와 
비교하여 이상 유무를 판단하는 것에 있다. 
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본 논문은 Over-Representation Analysis (ORA), Functional Class Score 
(FCS) 등의 기존에 알려진 그룹 대 그룹에서의 유전자 네트웍 분석법의 
개인향 분석법을 제공한다. 이 방법을 사용하여 본 논문에서는 개인의 
유전자 네트웍 이상 점수 (individualized pathway aberrance score : iPAS)를 
제시 한다. 
본 논문의 방법을 두가지 종류의 암종 (폐 선암종, 대장암) 
유전자 발현 데이터에 적용하여 유용성을 보였다. 페 정상 조직과 대장 
점막 정상 조직의 유전자 발현 데이터를 참조 표준으로 삼고, 각 암 
환자 한 사람씩의 유전자 네트웍의 이상을 분석 하였다. 본 논문의 
방법은 기존의 연구에서 밝혀진 환자 생존률과 관련된 유전자 네트웍 
이상을 정확히 탐지 하였다. 본 논문의 방법은 기존에 방법이라고 할 수 
있는, 환자 한명의 정보를 해당 환자가 속한 코호트의 정보를 참조 
표준으로 사용하여 해석하는 것 보다, 더 높은 재현성을 보였다. 재현성 
측정은 서로 다른 데이터군을 사용하여, 유전자 네트웍 발굴군에서 
발굴한 생존 관련 유전자 네트웍이, 발굴에 사용되지 않았던 
데이터군에서도 생존에 유의한 영향을 미치는지 측정하였다.  
또한 해당 방법은 유전자 네트웍의 특징을 기반으로 환자와 
정상을 구분할 수 있다. 특별히 ‘amino acid synthesis and interconversion’ 
pathway 의 경우 폐 선암을 독립적인 검증을 위한 데이터군에서도 AUC 
0.982 로 잘 구분할 수 있다. 또한 본 논문에서 제시한 방법은 
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돌연변이가 유전자 발현 네트웍에 미치는 영향을 정량화 할 수 있는 
방법으로 사용될 수 있다. 본 방법을 사용하였을 때 유방암의 유전자 
발현 네트웍에 통계적으로 유의한 영향을 미치는 PI3KCA, TP53, RB1 의 
세 유전자를 찾을 수 있었고, 이는 알려진 유방암의 지식과 일치한다.  
본 논문의 임상적인 의의는 환자 한 사람에서 정상 조직 정보가 
없을 때, 한 사람의 암을 유전자 네트웍 측면에서 해석 할 수 있도록 한 
것이다. 이러한 방법은 데이터에 기반한 것으로서, 축적되고 있는 정상 
조직 데이터를 사용하여, 더욱 정확한 데이터 기반 의사 결정을 하는 
데에 기여할 수 있다. 본 논문의 방법은 유전자 발현 뿐 아니라 돌연 
변이 분석과도 연계되어, 환자의 암을 유발하는 유전자 네트웍을 
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